Plasma microRNA profiling distinguishes patients with frontotemporal dementia from healthy subjects

Neurobiol Aging. 2019 Dec:84:240.e1-240.e12. doi: 10.1016/j.neurobiolaging.2019.01.024. Epub 2019 Feb 5.

Abstract

The purpose of this study was to develop an easy and minimally invasive assay to detect a plasma miRNA profile in frontotemporal dementia (FTD) patients, with the final aim of discriminating between FTD patients and healthy controls (HCs). After a global miRNA profiling, significant downregulation of miR-663a, miR-502-3p, and miR-206 (p = 0.0001, p = 0.0002, and p = 0.02 respectively) in FTD patients was confirmed when compared with HCs in a larger case-control sample. Moreover, miR-663a and miR-502-3p showed significant differences in both genders, whereas miR-206, only in male subjects. To obtain a discriminating measure between FTD patients and HCs, we calculated a combined score of the 3 miRNAs by applying a Bayesian approach and obtaining a classifier with an accuracy of 84.4%. Moreover, for men, combined miRNA levels showed an excellent sensitivity (100%) and a good specificity (87.5%) in distinguishing FTD patients from HCs. All these findings open new hypotheses in the pathophysiology and new perspectives in the diagnosis of a complex pathology as FTD.

Keywords: Biomarkers; Frontotemporal dementia; Gender; MicroRNAs; RT-qPCR.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Frontotemporal Dementia / blood
  • Frontotemporal Dementia / genetics*
  • Healthy Aging*
  • Humans
  • MicroRNAs / blood*

Substances

  • MicroRNAs